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Abstract
Abnormal a-synuclein aggregates are hallmarks of a number of neurodegenerative diseases. Alpha synuclein and b-
synucleins are susceptible to post-translational modification as isoaspartate protein damage, which is regulated in vivo by
the action of the repair enzyme protein L-isoaspartyl O-methyltransferase (PIMT). We aged in vitro native a-synuclein, the a-
synuclein familial mutants A30P and A53T that give rise to Parkinsonian phenotypes, and b-synuclein, at physiological pH
and temperature for a time course of up to 20 days. Resolution of native a-synuclein and b-synuclein by two dimensional
techniques showed the accumulation of a number of post-translationally modified forms of both proteins. The levels of
isoaspartate formed over the 20 day time course were quantified by exogenous methylation with PIMT using S-Adenosyl-L-
[3H-methyl]methionine as a methyl donor, and liquid scintillation counting of liberated 3H-methanol. All a-synuclein proteins
accumulated isoaspartate at ,1% of molecules/day, ,20 times faster than for b-synuclein. This disparity between rates of
isoaspartate was confirmed by exogenous methylation of synucleins by PIMT, protein resolution by one-dimensional
denaturing gel electrophoresis, and visualisation of 3H-methyl esters by autoradiography. Protein silver staining and
autoradiography also revealed that a-synucleins accumulated stable oligomers that were resistant to denaturing conditions,
and which also contained isoaspartate. Co-incubation of approximately equimolar b-synuclein with a-synuclein resulted in a
significant reduction of isoaspartate formed in all a-synucleins after 20 days of ageing. Co-incubated a- and b-synucleins, or
a, or b synucleins alone, were resolved by non-denaturing size exclusion chromatography and all formed oligomers of
,57.5 kDa; consistent with tetramerization. Direct association of a-synuclein with b-synuclein in column fractions or from in
vitro ageing co-incubations was demonstrated by their co-immunoprecipitation. These results provide an insight into the
molecular differences between a- and b-synucleins during ageing, and highlight the susceptibility of a-synuclein to protein
damage, and the potential protective role of b-synuclein.
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The family of cytoplasmic synuclein proteins that comprises a-
synuclein, b-synuclein, and c-synuclein are thought to function in
synaptic vesicle release and transmission, and neuronal plasticity.
Alpha and b-synucleins are highly homologous proteins (62%
identical) that are co-localised within presynaptic nerve terminals
in the central nervous system, whereas c-synuclein is primarily
expressed in the peripheral nervous system [1–3].
Abnormal a-synuclein accumulations are hallmarks and
presumed pathogenic events in a number of age-related diseases,
collectively termed synucleopathies, and include Parkinson’s
disease (PD), Alzheimer’s disease (AD), dementia with Lewy
bodies (DLB), and multiple system atrophy (MSA) [3]. Native a-
synuclein is an unfolded protein, but can undergo aggregation and
fibril formation in a complex process that can be influenced by the
local and external environment. Whether a-synuclein aggregates
contribute to disease pathology, and/or induce cellular changes
that trigger cellular toxicity and cell death is still under
investigation, but a causative role of abnormal a-synuclein
function is underscored by rare autosomal dominant mutants of
a-synuclein, or a-synuclein gene multiplication, which give rise to
Parkinsonian phenotypes [4–7]. Additionally, experimental animal
models such as transgenic mice that express a-synuclein develop a
Parkinsonian movement disorder and exhibit loss of dopaminergic
neurons, a characteristic feature of PD [8].
One of the strategies employed to combat or curb disease
pathology has been the development of therapies directed toward
reducing a-synuclein aggregation and/or fibril formation [9,10].
An example of this has been the co-incubation of b-synuclein with
a-synuclein, since these two proteins directly bind one another,
and their association reduces a-synuclein aggregation/fibril
formation, and ameliorates a-synuclein-induced neurodegenera-
tive manifestations [9–14].
The functional activity and aggregation potential of a-synuclein
may be influenced by post-translational modifications that include
phosphorylation, ubiquitination, and protein truncation [15].
Previously, our proteomic studies also identified a-synuclein and
b-synuclein as substrates of methylation by the protein repair
enzyme, protein L-isoaspartate O-methyltransferase (PIMT) [16].
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PIMT is a ubiquitously expressed methyltransferase which
methylates isoaspartic acid residues in cytosolic and nuclear
proteins. Isoaspartate is a protein post-translational modification
that arises as a result of the lability of asparagine and aspartic acid
residues within peptide and protein chains. Non-enzymatic
deamidation of an asparagine residue or dehydration of an
aspartic acid residue can give rise to a five-carbon succinimide,
whose subsequent hydrolysis can generate a return of an aspartic
acid (,30% of yield), or an isoaspartatic acid residue (,70% of
yield). Isoaspartate formation produces a ‘kink’ in a peptide chain
since the peptide backbone now contains an extra methylene
group and is maintained through the b-carbonyl group of the
generating amino acid – refer to Figure 1. This alteration of
protein structure may be concomitant with loss of protein function,
so isoaspartate formation is considered a common and generally
undesired form of protein damage [16–24].
PIMT utilises S-adenosylmethionine (SAM) as a methyl donor
to carboxyl-methylate isoaspartate forming a methyl ester that
readily hydrolyses under physiological conditions to liberate
methanol, and reform the five-carbon succinimide. Succinimide
hydrolysis will again yield aspartate and isoaspartate products.
Hence successive rounds of PIMT methylation of isoaspartate,
succinimide formation and then hydrolysis, will form aspartic acid
residues within normal peptide linkages, and this has been shown
to be concomitant with restoration of protein function - refer to
Figure 1 [16–24].
The importance of functional activity of PIMT and repair of
isoaspartate peptide linkages was illustrated by the production and
analysis of PIMT knockout (Pcmt12/2) mice [16,25–31]. These
mice accumulate isoaspartate protein damage in tissues that
express PIMT, with the highest levels of isoaspartate damage
detected within neuronal tissue proteins [16]. Pcmt12/2 mice
display neuronal abnormalities that include aberrant synaptic
neurotransmission, and most animals succumb to a terminal
epileptic seizure by two months of age [16,25–31].
The byproduct of PIMT methylation reactions is S-adenosyl-
homocysteine (SAH), which is a product inhibitor of many
methyltransferases including PIMT [32–37]. The protein repair
activity of PIMT is therefore susceptible to agents that impinge
upon the methionine metabolic pathway and result in a change in
the ratio of SAM:SAH [32–37]. Agents that lower the SAM:SAH
ratio, for example, excessive alcohol consumption, folate deficien-
cy, or inhibitors of SAH hydrolase, result in an inhibition of PIMT
activity, and an increase in isoaspartate protein damage within
cellular proteins [33–37].
Although a- and b-synucleins are highly homologous proteins,
they may display unique levels of protein post-translational
modifications which could influence their functional (patho)phys-
iological activities. The formation of protein post-translational
Figure 1. Isoaspartate protein damage formation and PIMT-mediated protein repair. Within a peptide backbone, non-enzymatic
deamidation of an asparagine-Xaa linkage or dehydration of an aspartic acid-Xaa linkage can give rise to a five-carbon succinimide (indicated by the
dashed arrows). Succinimide hydrolysis (OH2) yields an isoaspartate residue (major product, indicated by the dashed arrow), or an aspartic acid
(minor product, indicated by the right solid arrow). PIMT utilises SAM to carboxyl-methylate the isoaspartate forming a methyl ester that readily
hydrolyses under physiological conditions to liberate methanol and reform the five-carbon succinimide (lower solid arrow). Subsequent succinimide
hydrolysis will again yield isoaspartate or ‘repaired’ aspartate products (right solid arrow). PIMT activity is influenced by the levels of SAM and SAH,
which are likewise governed by the enzyme and metabolite levels of the methionine metabolic pathway.
doi:10.1371/journal.pone.0061442.g001
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modification as isoaspartate has been modelled by ageing proteins
in vitro at physiological pH and temperature, and quantitated by
exogenous methylation with PIMT using 3H-SAM [22,23,38,39].
Our previous proteomic study demonstrated that murine a-
synuclein and murine b-synuclein form isoaspartate protein
damage in vivo and are substrates of PIMT [16]. Human a- and
human b-synucleins possess 95 and 97% sequence homology
respectively to their murine counterparts (Figure 2). The aim of
this study was to examine the formation of isoasparate protein
damage after in vitro aging human a-synuclein, human b-synuclein,
and the mutants of human a-synuclein, A30P and A53T that can
trigger familial Parkionsonian phenotypes.
Experimental Procedures (Materials and Methods)
Recombinant human a-synuclein (MW=14460, product
AG938), b-synuclein (MW=14288, product AG946), A30P
mutant a–synuclein (MW=14486, product AG942), and A53T
mutant a-synuclein (MW=14490, product AG940) were pur-
chased from Chemicon International, USA. Immobilised pH
gradient (IPG) strips (pH 4–7, 7 cm length) were purchased from
BioRad, with all isoelectric focussing performed using a BioRad
Protean isoelectric focussing cell. NuPAGE Novex pre-cast gels (4–
12% Bis-Tris gels for 1D SDS-PAGE and 4–12% Bis-Tris Zoom
gels for 2D PAGE analysis), 2-(N-morpholino)ethanesulfonic acid
(MES)-SDS running buffer, transfer buffer, SeeBlue Plus2
prestained gel standards, and Safe stain were all bought from
the Invitrogen Corporation. All other SDS-PAGE reagents were
purchased from Sigma. Isoquant isoaspartate detection kits were
purchased from the Promega Corporation. S-Adenosyl-L-[3H-
methyl]methionine (37 MBq/ml), destreak reagent, and PlusOne
silver staining kits were purchased from Amersham Biosciences
UK. Bovine recombinant PIMT provided with the Isoquant kit
was used for exogenous isoaspartate methylation prior to protein
separation using 1D or 2D-PAGE. Rabbit polyclonal antibody
specific for a-synuclein (sc-7011-R) was purchased from Santa-
Cruz, USA. Rabbit polyclonal antibody specific for b-synuclein
(SA3405) was purchased from Enzo. Goat anti-rabbit immuno-
globulins-horseradish peroxidase conjugated secondary antibody
(P0448) was purchased from Dako, UK.
Mice
Brain cytosolic proteins from Pcmt1+/+ (wild-type) and Pcmt12/
2 (PIMT knockout (KO)) mice were kindly provided by the
laboratory of Professor Steven Clarke (University of California at
Los Angeles). Cytosolic proteins were shipped on dry ice to the
laboratory of WGC, and maintained at 280uC until required for
analyses. The production and breeding conditions for generation
of these mice have been reported previously [25,28]. Mice were
monitored by on-site veterinarians, with all protocols undertaken
in strict accordance with the recommendations for the Care and
Use of Laboratory Animals, and approval by the University of
California at Los Angeles Institutional Animal Care and Use
Committee, under approved protocol ARC #1993-109-62. The
preparation of Pcmt12/2 brain cytosolic proteins were as
described previously [40].
In vitro aging of synucleins
Synucleins were dissolved in an in vitro aging buffer of 50 mM
K-HEPES pH 7.4, 1 mM EDTA, 5% glycerol, 0.02% sodium
azide to a concentration of 1 mg/ml (approximately 70 mM).
Proteins were aged at 37uC for up to 20 days, with protein samples
removed after 0, 2, 5, 9, and 20 days of in vitro ageing, immediately
flash frozen, and stored at 280uC until required. These buffer
conditions are similar to those that have been used in other in vitro
ageing studies [22,23,38,39].
Figure 2. Amino acid sequence alignment of human and mouse a-synuclein, and human and mouse b-synuclein. Identical amino acids
are marked with an asterisk. The positions of the human a-synuclein familial mutants A30P and A53T are underlined. Aspartic acid and asparagine
residues that may give rise to isoaspartate formation are shown in bold.
doi:10.1371/journal.pone.0061442.g002
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Two dimensional polyacrylamide gel electrophoresis (2D-
PAGE)
Six hundred mg of Pcmt12/2 brain cytosolic extract was
incubated either with or without 5 mg of 20 day in vitro aged a-
synuclein or 20 day in vitro aged b-synuclein for resolution by 2D-
PAGE and Coomassie protein staining. For autoradiography
studies, 2D-PAGE was preceded by methylation of 5 mg of 20 day
in vitro aged a-synuclein or 20 day in vitro aged b-synuclein in a
buffer of 50 mM K-MES, pH 6.2, containing 20 mM 3H-SAM
(8250 dpm/pmol final specific activity) in a final volume of 20 ml.
Methylation was initiated by the addition of 5 ml of exogenous
recombinant bovine PIMT (2.4 mM final concentration), and
continued for 30 minutes at 30uC. This exogenous methylation of
the L-isoaspartate synuclein proteins resulted in the formation of
3H-methyl esters. Experimental conditions were then employed to
preserve base-labile 3H-methyl esters to enable isoaspartate
detection via autoradiography [16]. Proteins for 2D-PAGE and
Coomassie staining or autoradiography were processed similarly.
Proteins were precipitated by incubation with 700 ml of protein
precipitation solution (acetone:diethyl ether (2:1 (v/v)), and
samples placed on ice for 15 minutes. Precipitated protein was
collected by centrifugation at 5000 rpm for 3 minutes, washed
three times with ether:industrial methylated spirit:water (10:7:2 (v/
v/v)), air dried, and then proteins dissolved in a rehydration buffer
(9.8 M urea, 2% (w/v) CHAPS, 0.5% IPG buffer) containing
12.5 ml/ml of the anti-oxidant destreak reagent, at room
temperature for 1 hour. Solubilised protein was actively rehydrat-
ed into 7 cm pH 4–7 IPG isoelectric focusing strips for 16 hours at
50 V, and then focussed for 16 hours according to the manufac-
turer’s guidelines. Focussed strips were washed in an equilibration
buffer of 0.375 M Tris/HCl pH 6.8, 6 M urea, 2% SDS, 20%
glycerol, containing 2% (w/v) dithiothreitol (DTT) for 10 minutes,
and then similarly washed with the same buffer in which 2.5% (w/
v) iodoacetamide replaced the DTT. After this reduction and
alkylation, strips were equilibrated in MES running buffer before
application to the top of NuPage Zoom gels, and protein
separation by SDS-PAGE [16]. Proteins resolved by 2D-PAGE
were fixed by washing in 50% methanol, 10% acetic acid, and
then stained with colloidal Coomassie blue according to the
manufacturer’s recommendations. 2D-PAGE co-migrational ex-
periments containing Pcmt12/2 brain cytosolic proteins and a-
synuclein or b-synuclein were performed 2–3 times with each
synuclein. Two-dimensional PAGE resolution of Pcmt1+/+ or
Pcmt12/2 brain cytosolic proteins have been performed greater
than 5 times with each genotype, with migrational positions of a-
synuclein and b-synuclein previously validated [16].
Quantitation of isoaspartate levels in synucleins by a
methanol diffusion assay
Isoaspartate levels within synuclein proteins were quantified
using an Isoquant kit by exogenous methylation with PIMT in a
final volume of 50 ml utilising 20 mM 3H-SAM (1 mCi/reaction,
2220 dpm/pmol final specific activity), in a buffer of 100 mM
sodium phosphate pH 6.8, containing 1 mM EGTA, 0.16%
Triton X-100, and 0.004% sodium azide (final concentrations) for
30 minutes at 30uC. Methylation was terminated and the methyl
esters hydrolyzed by the addition of an equivalent volume of
CAPS (pH 10), 5% SDS, 2.2% methanol, 0.1% m-cresol purple,
and the samples retained on ice for 10 minutes. Fifty microlitres
from each of the samples was then spotted onto a sponge inserted
into the cap of a scintillation vial. The samples were incubated for
60 min at 40uC to volatilize 3H-methanol from the methylated
proteins into 10 ml of scintillation fluid, which was then counted
for radioactivity. For each time point, one and a quarter
micrograms of aged synucleins were assayed in duplicate from
which an average was taken, and methylation blank subtracted.
Fifty picomoles of isoaspartate-containing delta sleep-inducing
peptide were similarly methylated to provide a reference level of
isoaspartate methylation [16]. Levels of isoaspartate were analysed
by one way analysis of variance (ANOVA) with Bonferroni post-
test using Prism software. A p value of ,0.05 was regarded as
statistically significant. All data points for isoaspartate quantitation
are representative of a mean and SEM from 3–5 independent
experiments.
One dimensional polyacrylamide gel electrophoresis (1D-
PAGE)
Synuclein proteins were methylated by exogenous PIMT using
3H-SAM as described above for 2D-PAGE, but methylation
terminated by the addition of a quarter of a volume of 56
concentrated reducing solution (10% SDS and 500 mM DTT)
and the samples heated for 10 minutes at 50uC. One quarter of a
volume of 56Laemmli sample buffer was added (250 mM Tris/
HCl, pH 6.8, 40% (v/v) glycerol, 5% (w/v) SDS, 0.005% (w/v)
bromophenol blue) and synuclein proteins (2.5 mg/gel lane)
resolved on 4–12% Bis/Tris gels for 2 hours at 125 V using
MES running buffer (pH 7.3) run in an X Cell surelock gel tank
(Invitrogen). Gel resolved synuclein proteins were stained with
silver and then photographed using a Fugi E900 digital camera.
Alternatively, gel separated synucleins were transferred at 80 V for
2 hours to a polyvinylidene difluoride (PVDF) membrane for
either autoradiography or Western blotting.
Autoradiography
Approximately 0.25 ml of 100 KBq 14C-amino acid mixture
(1.85 MBq/ml, Amersham) was spotted onto the PVDF mem-
brane at the positions of the molecular weight markers to enable
their visualisation during autoradiography. Autoradiography was
performed using a microchannel plate (MCP) autoradiographic
imager. These novel devices are able to produce real-time digital
autoradiographic images, from a detection threshold of 6 dpm/
mm2, and an intrinsic background noise of ,561026 counts/
second per pixel measurement [41]. This low signal threshold, and
linearity over six orders of signal magnitude ably suit the detection
and quantitation of relatively low energy b-particle (tritium)
protein radiolabelling [41]. For proteins resolved by 1D-PAGE, a-
synucleins were autoradiographed for 24 hours, and b-synuclein
for 48 hours. For 2D-PAGE, PVDF membranes were autoradio-
graphed for 48 hours.
Western (immuno) blotting
PVDF membranes were stained with Coomassie blue Safe stain
for 30 minutes, and then air-dried. Membranes were destained
with 50% methanol, 10% acetic acid and then washed in
phosphate buffered saline (PBS) containing 0.05% Tween-20
(PBS-T). Membranes were blocked in the same buffer containing
5% (w/v) milk fat, and then probed with the following antibodies
in blocking buffer overnight at 4uC: rabbit polyclonal antibody
specific for a-synuclein at a 1:250 dilution, or rabbit polyclonal
antibody specific for b-synuclein at a 1:250 dilution (Enzo). Blots
were washed, and then incubated with a goat anti-rabbit
immunoglobulins-horseradish peroxidase-conjugated secondary
antibody at 1:1000 dilution for 1 hour at room temperature.
Blots were similarly washed and then synuclein localisation
visualised using enhanced chemiluminescence (ECL) (Pierce).
Light generated from ECL was either captured on CL-Xposure
Molecular Ageing of Synucleins
PLOS ONE | www.plosone.org 4 April 2013 | Volume 8 | Issue 4 | e61442
X-ray film (Pierce), or using a closed circuit device (ChemiDoc,
BioRad). X-ray films were scanned on an Epson stylus XS400
flatbed scanner.
Matrix assisted laser-desorption ionisation-time of flight
(MALDI-TOF) mass spectrometry
Silver stained proteins resolved by 1D PAGE were excised from
gels and transferred to a 96-well plate using an automated
MassPrep robotic system (ProteomeWorks, BioRad). After protein
trypsinolysis, MALDI-TOF mass spectrometry was performed
using a Micromass MALDI (Waters, UK) as described in a
previous publication [42]. A number of intact singularly charged
peptides in the mass range of 800–3000 Da were identified, and
the masses applied to a search algorithm (MASCOT peptide mass
fingerprint) to screen protein databases, such as SwissProt for
peptide mass matches to enable protein identification.
Column chromatography
Size exclusion chromatography was performed using a Superose
12 (GE Healthcare) column run on an AKTA FPLC system
(Amersham Phamacia). Proteins were separated in a buffer of
50 mM Tris/HCl pH 7.4, 100 mM NaCl, 1 mM EDTA and 5%
(v/v) glycerol at a flow rate of 0.5 ml/min. Protein samples (20–
50 mg/run in 200 ml final volume) were resolved and 0.25 ml
fractions collected. The approximate molecular weight of eluted
synuclein proteins were estimated from comparison of their elution
volumes with those of proteins of known molecular weight (gel
filtration standards, Biorad: thyroglobulin (670 kDa), c-globulin
(158 kDa), ovalbumin (44 kDa), myoglobin (17 kDa), and vitamin
B12 (1.35 kDa). Chromatography was performed at least once on
all a, b, and co-incubation time points, with representative
chromatograms displayed in Figures. Peak column fractions were
concentrated using Microcon concentrators (3 kDa cut-off, Fish-
er), and proteins resolved by 1D SDS-PAGE. Proteins were
stained with colloidal Coomassie blue (Invitrogen) and Western
blotted as described above.
Immunoprecipitation (IP) analyses
Approximately 20 mg of b-synuclein from in vitro aged reactions,
or from peak column fractions from Superose 12 chromatography
were precleared at 4uC for 1 hour, and then b-synuclein
immunoprecipitated by the addition of 2 mg of anti-b-synuclein
antibody or control rabbit serum (Dako), and end-over-end
rotation on a carousel for 16 hours at 4uC. Immunoprecipitation
was similarly performed on co-incubation mixtures of a- and b-
synucleins. Immune complexes were captured by the addition of
protein-A-agarose for 2 hours at 4uC, and then washed four times
with a wash buffer of 20 mM Tris/HCl pH 7.5, 150 mM NaCl,
1% (v/v) Triton X-100. Protein was dissociated from the antibody
by incubation in 20 ml of Laemmli sample buffer (Invitrogen) and
heating at 70uC for 10 minutes. Proteins were resolved by 1D
SDS-PAGE, transferred to a PVDF membrane, and then blotted
for a- or b-synuclein as described in Figure legends.
Results
After in vitro aging at physiological pH and temperature for 20
days, recombinant human synucleins displayed similar protein
separation character to that of their corresponding murine
proteins from Pcmt12/2 brains, when resolved by co-migrational
2D-PAGE – Figure 3. Twenty day in vitro aged a-synuclein alone
was resolved by 2D-PAGE into two major Coomassie stained
proteins of pI ,4.6–4.7, and two minor protein spots of
approximate pI 4.2 and 4.4 and molecular weight ,10 kDa
(Figure 4, upper left panel). Two-dimensional PAGE resolution of
20 day in vitro aged b-synuclein alone typically showed one broad
Coomassie stained protein at a pI of ,4.4, and a number of other
minor stained protein spots in the pI range of 4.2–4.8 and
molecular weight of ,10 kDa (Figure 4, lower left panel). In
addition, a-synuclein and b-synuclein were methylated with 3H-
SAM using exogenous PIMT, and then resolved by 2D-PAGE and
protein radiolabelling of isoaspartate, as 3H-methyl esters,
visualised by autoradiography. Noteworthy was that aged a-
synuclein had accumulated significantly more isoaspartate than
aged b-synuclein, as evidenced by the relatively higher autoradio-
graphic signal – Figure 4, right panels. Both major Coomassie
stained protein forms of a-synuclein contained isoaspartate peptide
linkages, and isoaspartate was also localised to the minor lower
molecular weight protein spots. The single prominent Coomassie
stained b-synuclein protein only accumulated low levels of
isoaspartate, as did the additional minor low molecular weight
forms of this protein, and the ,38 kDa spot that arose from
incomplete 2D-PAGE resolution of b-synuclein protein – Figure 4,
right panels.
Figure 3. 2D-PAGE of Pcmt12/2 mice brain cytosolic proteins.
Pcmt12/2 brain cytosolic proteins were resolved by 2D-PAGE and
proteins stained with colloidal Coomassie blue (upper panel). Pcmt12/
2 brain cytosolic proteins co-incubated with 5 mg of a-synuclein
(middle panel) or 5 mg of b-synuclein (lower panel) prior to co-
migrational 2D-PAGE. Protein spots identified as a-synuclein (right spot,
ringed) and b-synuclein (left spot, ringed) were increased in their
protein staining intensity with co-migrational analyses.
doi:10.1371/journal.pone.0061442.g003
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To investigate this disparity between the levels of isoaspartate
that accumulated within aged a-synuclein compared to aged b-
synuclein, we in vitro aged both proteins and removed samples for
analysis after 0, 2, 5, 9, and 20 days of ageing. Additionally, we
examined the formation of isoaspartate over the same time course
for the autosomal dominant a-synuclein mutants A30P and A53T;
mutant proteins that trigger familial PD. Levels of isoaspartate
were quantified by exogenous methylation with 3H-SAM using
PIMT, and liquid scintillation counting of 3H-methanol in a
methanol diffusion assay. All a-synuclein proteins accumulated
isoaspartate at a rate of ,1% of molecules per day, whereas with
b-synuclein this was reduced to ,0.05% per day – Figure 5. This
differential accumulation of isoaspartate between the a-synucleins
and b-synuclein was further validated by isoaspartate methylation
with 3H-SAM using exogenous PIMT, and then protein resolution
of the 3H-methyl esters by 1D PAGE and their visualisation using
digital autoradiography – Figure 6.
In addition, one dimensional PAGE and autoradiography
revealed that native a-synuclein, and the familial mutant forms
of a-synuclein; A30P and A53T, formed protein oligomers after in
vitro ageing that were resistant to the denaturing conditions of
SDS-PAGE. That these oligomers were a-synuclein protein was
validated by both Western blotting with a specific anti-a-synuclein
antibody, and excision of each protein band and mass spectrom-
etry peptide mass fingerprinting. A sample Western blot and
peptide mass fingerprint has been included as Supplementary
(supporting) data. In contrast to a-synucleins, b-synuclein did not
form these SDS-PAGE resistant oligomers over this 20 day time
course.
A number of independent studies have suggested a neuropro-
tective role of b-synuclein due to its ability to associate with a-
synuclein and reduce a-synuclein aggregation/fibril formation,
and ameliorate a-synuclein-induced neurodegenerative manifes-
tations [9–14,43]. To investigate the influence of b-synuclein upon
the formation of isoaspartate damage within a-synucleins, we co-
incubated approximately equimolar b-synuclein with each a-
synuclein, and quantified the rate of formation of isoaspartate over
a time course of up to 20 days of in vitro ageing. At intervals of 0, 2,
5, 9, and 20 days, synuclein proteins were removed and
methylated with 3H-SAM using exogenous PIMT, and the level
of isoaspartate present quantified by a methanol diffusion assay.
Co-incubation of b-synuclein with a-synuclein resulted in a
significant reduction in isoaspartate in native a-synuclein, and
A53T mutant a-synuclein after 5 days, and after 2 days for A30P
mutant a-synuclein - refer to Figure 7 left panels. This reduction of
a-synuclein isoaspartate levels reached a significant 72.262.8%,
84.362.9%, and 47.963.74% (p,0.001) within native a-synu-
clein, A30P a-synuclein, and A53T a-synuclein respectively after
20 days of in vitro ageing – refer to Figure 7 left panels. This
lowering of isoaspartate formation within the a-synucleins was also
validated by methylation with 3H-SAM using exogenous PIMT,
Figure 4. 2D-PAGE of in vitro aged synucleins. Five mg of 20 day in vitro aged a-synuclein (upper panels) or 5 mg of 20 day in vitro aged b-
synuclein (lower panels) were methylated with 3H-SAM using exogenous PIMT, and proteins resolved by 2D-PAGE. Proteins were stained with
Coomassie (left panels), and methylation of isoaspartate visualised by autoradiography (right panels).
doi:10.1371/journal.pone.0061442.g004
Figure 5. Quantitation of isoaspartate protein damage after in
vitro ageing of synucleins. Native a-synuclein, b-synuclein, A30P
mutant a-synuclein, or A53T mutant a-synuclein were in vitro aged over
a time course of 20 days. Two and a half mg of protein was removed
after 0, 2, 5, 9, and 20 days of in vitro ageing and the level of
isoaspartate formation quantified by a methanol diffusion assay.
doi:10.1371/journal.pone.0061442.g005
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and gel separation of the 3H-methyl esters by 1D PAGE and their
visualisation using autoradiography – Figure 7, right panels.
We predict that the known physical interaction of a-synuclein
with b-synuclein [10–14,43] can provide a mechanism for
suppression of a-synuclein isoaspartate formation during co-
incubation experiments. To assess this we resolved co-incubated
a-synculein and b-synuclein by size exclusion chromatography in
non-denaturing buffer, with results presented in Figure 8. Incu-
bation of a- and b-synuclein with one another, or as individual
proteins, resulted in the detection of two column peaks: Peak 1
eluted at ,10.89 ml, and Peak 2 eluted at ,15.20 ml. Peak 1
elution corresponded to a protein of molecular weight of
,57.5 kDa, consistent with the formation of synuclein tetramers.
Peak 2 was devoid of protein and was an artefact of the in vitro
ageing buffer – Figure 8, Part A. Fractions from Peak 1 were
concentrated and proteins resolved by denaturing 1D SDS-PAGE
– Figure 8, Part B, upper panel. Co-incubation of a- and b-
synucleins was recovered as a mixture of both proteins in a diffuse
Figure 6. 1D-PAGE resolution of in vitro aged and methylated
synucleins, and methyl ester autoradiography. Synuclein pro-
teins were methylated with 3H-SAM using exogenous PIMT, resolved by
1D PAGE and proteins stained with silver (left panels), or proteins
transferred to PVDF and the level of isoaspartate methylation visualised
by autoradiography (right panels). Wild-type and mutant a-synuclein
proteins formed stable protein oligomers that contained isoaspartate
peptide linkages (marked with arrowheads).
doi:10.1371/journal.pone.0061442.g006
Figure 7. Quantitation of isoaspartate formation during in vitro
ageing of a-synuclein either with or without co-incubation with
b-synuclein, and co-incubation autoradiography. Alpha-synu-
clein, A30P mutant a-synuclein, or A53T mutant a-synuclein were in
vitro aged either with or without b-synuclein over a time course of up to
20 days. Two and a half mg of protein was removed after 0, 2, 5, 9, and
20 days of in vitro ageing and the level of isoaspartate formation
quantified by a methanol diffusion assay (left panels). Black filled
columns correspond to a-synuclein isoaspartate values, grey filled
columns correspond to isoaspartate levels from a-synuclein co-
incubated with b-synuclein. Co-incubation of b-synuclein with a-
synucleins significantly reduced total isoaspartate formed during the
in vitro ageing time course. Significance is marked with an asterisk:
*p,0.01; **p,0.001. Synuclein proteins from co-incubation experi-
ments were methylated with 3H-SAM using exogenous PIMT, resolved
by 1D PAGE, and isoaspartate methylation visualised by autoradiogra-
phy (right panels). Stable a-synuclein protein oligomers that contained
isoaspartate peptide linkages are marked with arrowheads.
doi:10.1371/journal.pone.0061442.g007
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band of ,14.5 kDa after Coomassie staining. Peak 1 fraction
analysis by SDS-PAGE of a- or b-synucleins when run as single
proteins also only recovered monomeric forms of the proteins. The
identity of synuclein proteins was confirmed by Western blotting -
Figure 8B middle panels.
The study of Israeli & Sharon (2009) has shown that native (in
vivo) a- and b-synucleins can exist as hetero-oligomers [43].
However, for co-incubated synuclein proteins our size exclusion
chromatography is unable to distinguish between the elution
profile of homo-oligomers or hetero-oligomers. Thus to confirm
molecular interaction of a- and b- synucleins we immunoprecip-
itated b-synuclein directly from in vitro aged co-incubated mixtures,
or from Superose 12 column peak fractions from co-incubation
analyses, and then blotted for a-synuclein. In either case, after
immunoprecipitation with a b-synuclein specific antibody, a-
synuclein was detected by subsequent Western blotting –
Figure 8B, lower panels. The ability of the b-synuclein antibody
to specifically immunoprecipitate b-synuclein was also confirmed,
and was not achieved using control rabbit serum which was only
immunoreactive against antibody chains (,25 kDa light chain is
shown). The b-synuclein antibody was also unreactive against a-
synuclein (Figure 8B, lower panels).
Discussion
The major recognised cellular function of PIMT is to limit the
accumulation of detrimental isoaspartate peptide linkages that
form within nuclear and cytosolic proteins during protein ageing,
and as a consequence of cellular stresses [16–39]. Previously we
pioneered the use of a proteomic approach to resolve and
ultimately identify a number of the hitherto unknown murine
targets of PIMT; and this included a-synuclein and b-synuclein
[16]. Our 2D-PAGE approach was successful in separating the
highly homologous murine a-synuclein and murine b-synuclein
due to their differences in (theoretical) isoelectric point (pI): a-
synuclein, pI 4.74, and b-synuclein pI 4.38 [16]. Human a-
synuclein and b-synuclein possess high amino acid sequence
homology to their murine counterparts (95 and 97% respectively),
and also similar theoretical pIs: a-synuclein, pI 4.67, and b-
synuclein, pI 4.41. Hence the human synuclein proteins were also
able to be separated by 2D-PAGE, and migrated similarly to their
murine versions when resolved by co-migrational analyses. Thus
we assume that by similarity, these human synuclein proteins
would be substrates of human PIMT, and be useful as models of
accumulation of isoaspartate protein damage during in vitro protein
ageing. Furthermore, we chose to examine the human proteins
because of the known involvement of human a-synuclein in age-
related pathologies (synucleopathies) [3], and also the availability
of human synucleins as commercial, pure, recombinant proteins.
After in vitro ageing of a-synuclein at physiological pH and
temperature for 20 days, 2D-PAGE resolved a-synuclein into two
major Coomassie stained proteins, and b-synuclein to one broad
Coomassie stained protein, and additional minor protein spots of
both proteins. We assume these additional protein spots represent
protein post-translational modifications, minor levels of proteolysis
that occur during the in vitro ageing time course, and incomplete
2D-PAGE resolution. The presence of several similarly migrating
forms of a- and b-synuclein would concur with 2D-PAGE
separation of Pcmt12/2 knockout brain cytosolic proteins, which
also detected a number of other isoaspartate containing minor
protein spots juxtaposed to those identified as a-synuclein and b-
synuclein, although their identity has yet to be confirmed [16].
Since the synuclein proteins were stable for up to 20 days of in
vitro ageing (confirmed by Coomassie staining after 2D-PAGE) we
quantified the level of isoaspartate protein damage that accumu-
lated over that time course within these synucleins, and
additionally extended the analysis to include the A30P and
A53T mutants of a-synuclein. All a-synuclein proteins accumu-
lated isoaspartate at a similar rate of ,1% of molecules per day,
suggesting that the presence of a pathological mutation in a-
synuclein (A30P or A53T) does not greatly influence the initial rate
of formation of isoaspartate. These rates are slower than that
reported for the other PIMT in vivo substrates that have also been
aged in vitro: synapsin I (MW,74 kDa) at,6%, and tubulin (MW
,50 kDa) at ,2% of molecules formed isoaspartate per day
respectively [38,39], but presumably this is a reflection of the
smaller size of a-synucleins (MW ,14 kDa), and hence formation
of isoaspartate at fewer sites.
Noteworthy was that by comparison, the formation of
isoaspartate within b-synuclein was approximately 20 times slower
than that of the a-synucleins. These differences in rates and final
levels of isoaspartate formation between these synucleins were
further validated by exogenous isoaspartate methylation using
PIMT, protein resolution by 1D PAGE, and visualisation of 3H-
methyl esters by autoradiography. Silver staining of protein
removed during the in vitro ageing time course supported the
2D-PAGE analysis and showed that the major parent protein
remained intact for all synuclein forms, but a level of lower
molecular weight proteins existed, consistent with minor proteol-
ysis. In addition, stable a-synuclein oligomers that contained
isoaspartate were also present for all a-synuclein subtypes, and
these were resistant to the denaturing conditions of SDS-PAGE.
The level of oligomers formed that were detected by protein
staining increased with days of ageing. By comparison, stable
higher molecular weight oligomers of b-synuclein were not seen
during this ageing time course, although extension of b-synuclein
in vitro ageing to 30 days did result in detection of oligomers (our
unpublished observations). In support of our results, other
independent studies have reported the ability of a-synuclein, and
a-synuclein A30P and A53T mutants to readily form oligomers,
but not b-synuclein [10–12,14]. However, some of these studies
have been undertaken with protein incubations at 65uC, which
presumably accelerates the protein-protein interactions and
oligomerisation of a-synucleins, enabling oligomerisation detection
within hours rather than the days reported here for physiological
ageing conditions.
A number of studies have also described the neuroprotective
role of b-synuclein, suggesting that its interaction with a-synuclein
may slow or limit the ability of a-synuclein to aggregate, form
fibrils, and elicit a neurotoxic response [10–14,43]. This led us to
investigate if co-incubation of approximately equimolar b-
synuclein with a-synuclein affected the formation of isoaspartate
within a-synuclein, and also limited the formation of stable protein
oligomers. Co-incubation of b-synuclein with a-synuclein signif-
icantly reduced total isoaspartate formation at 5, 9, and 20 day
time points for all a-synuclein proteins. The mutant A30P a-
synuclein was the most responsive protein, with a significant
amelioration of isoaspartate protein damage detected after 2 days
of co-incubation, and reduced by 84% from that of A30P a-
synuclein alone after 20 days of ageing.
Stable protein oligomerisation of a-synucleins was not abolished
under these conditions, with oligomers visible after autoradiogra-
phy of radiolabelled isoaspartate methyl esters. Other studies have
reported the ability of b-synuclein to significantly reduce
oligomerisation of a-synuclein, although with some reports this
has required a molar excess of b-synuclein rather than equimolar
amounts of both proteins [10,11]. Beta-synuclein may therefore be
able to completely abolish both isoaspartate protein damage and
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protein oligomerisation within a-synucleins during this time course
if a molar excess of b-synuclein was employed. However, our
studies with cytosolic brain proteins from Pcmt1+/+ (wild-type), or
Pcmt12/2 mice suggest approximately similar a-synuclein and b-
synuclein protein levels exist [16], and this has recently been
supported by another group [43]. Hence we have restricted our
analyses to near equimolar b-synuclein and a-synuclein co-
incubations, although pathological situations may arise from an
imbalance in the relative expression levels of a- to b-synuclein, or
from b-synuclein mutations [44,45].
A direct binding/association of b-synuclein to a-synuclein is the
molecular mechanism reported by which b-synuclein is able to
suppress a-synuclein aggregation, fibril formation, and neurotox-
icity from in vitro and in vivo studies [10–14,43]. Furthermore,
studies have reported the presence of molecular interaction
domains within b-synuclein that specifically bind a-synuclein,
and these have been modelled using b-synuclein derived peptides
[46].
Hence we similarly assumed that b-synuclein associates with a-
synuclein and this sterically hinders the formation of isoaspartate
within a-synuclein. To investigate this association, we resolved a-
and b- co-incubated synucleins by non-denaturing size exclusion
chromatography. Resolution of co-incubated proteins, or a- or b-
synuclein alone, resulted in the detection of protein oligomers of
,57.5 kDa; indicative of tetramers. However, this chromatogra-
phy is not able to distinguish between the co-elution of homo-
oligomers or hetero-oligomers. Hence we confirmed molecular
interaction of a- and b-synucleins by their co-immunoprecipitation
from either Superose 12 column peak fractions, or from in vitro
aged co-incubated mixtures.
It will be of interest in future studies to ascertain which residues
within human and murine a-synucleins and human and murine b-
synucleins form isoaspartate peptide linkages, and how this post-
translational modification influences synuclein protein properties.
Human a-synuclein possesses 6 aspartic acid residues and 3
asparagine residues capable of giving rise to isoaspartate (residues
highlighted in Figure 2). By comparison, there are only 3 aspartic
acids and 1 asparagine in human b-synuclein, hence we might
speculate that the higher rate and amount of isoaspartate that
forms within a-synucleins arises from a greater number of
isoaspartate forming sites than b-synuclein.
The incidence and rates of deamidation and isoaspartate
formation have been examined using model peptides [47–49],
and the half-life of deamidation of human a-synuclein has also
recently been assessed [50]. These peptide model studies have
suggested that isoaspartate forms more readily at sequences at
which the side chain of the C-flanking amino acid is relatively
small and hydrophilic, as opposed to C-flanking amino acids
which are bulky or hydrophobic. Hence Asn-Gly, Asp-Gly, Asn-
His, and Asn-Ser sequences when present within flexible regions of
a protein displayed preference for isoaspartate formation via the
succinimide intermediate [47–49]. Alpha-synuclein does exist in
solution as a natively unfolded structure [51], a flexible
conformation(s) that may facilitate isoaspartate formation. Fur-
thermore, wild-type a-synuclein deamidation has been reported
for Asn103 and Asn122, residues within the unfolded carboxyl
region [50]. However, canonical isoaspartate hot-spot sequences
are absent from either human a-synuclein or human b-synuclein,
but the site specificity of isoaspartate formation and PIMT
carboxyl methylation may yet be better evaluated in future studies
using more proteins identified as bona fide in vivo substrates of PIMT
[16,52].
Although human and murine a-synucleins and b-synucleins
have nearly identical amino acid sequences, subtle differences in
their amino acid coding may result in profound changes in protein
properties. For example, the amino acid change of A53 to T53
that can result in rare Parkinonian phenotypes in humans is the
wild-type sequence in mice, but does not trigger a similar
pathology. It is interesting to note that of the other 6 amino acid
differences between the human a-synuclein and murine a-
synuclein sequences, 4 of these are either an asparagine or
asparatic acid residue, and therefore capable of forming
isoaspartate peptide linkages. Whether rates and levels of
isoaspartate differ greatly between human and murine a-
synucleins will be evaluated in future studies. For b-synuclein,
the four amino acids capable of forming isoaspartate are conserved
between the two species, but notably, Asp121 of the human b-
synuclein sequence is C-flanked by a proline residue, a sequence
less likely to facilitate isoaspartate formation, whereas the murine
sequence is C-flanked by a serine residue, in a sequence that would
favour isoaspartate formation. Thus we would predict that murine
b-synuclein would likely form isoaspartate at a higher rate and to a
higher level than human b-synuclein, but this will also need to be
evaluated with future studies. This supposition is in part supported
by our study of Pcmt12/2 mice which had accumulated similar
levels of isoaspartate in a- and b-synucleins (at the snap-shot
analysis of ,9 weeks of age) [16], suggesting that murine b-
synuclein may form isoaspartate to a similar level to that of murine
a-synuclein.
The functional consequences of isoaspartate protein damage in
a-synuclein or b-synuclein will also warrant future study. Alpha
and b-synucleins are co-localised presynaptic proteins and are
thought to function in synaptic vesicle release and transmission,
and neuronal plasticity [1–3]. Pcmt12/2 mice do display
neurodegenerative damage with an extensive gliosis [27,29], and
exhibit aberrant presynaptic neurotransmission in the hippocam-
pal CA3 region, learning deficits and impaired spatial memory as
determined by a Morris water maze [29]. This indicates a role of
PIMT and/or protein isoaspartate formation as key modulators of
proteins involved in neurotransmission and neurodegeneration,
Figure 8. Size exclusion chromatography and immunoblotting of synuclein proteins. (A) Alpha, b, or co-incubated mixtures of both
proteins were resolved by size exclusion chromatography on a Superose 12 column. Representative chromatograms from a buffer blank, and 20 day
in vitro aged a-synuclein, b-synuclein, and co-incubation mixtures are shown. Synuclein proteins eluted as a single peak (Peak 1) in two column
fractions at an elution volume of,10.89 ml, which corresponds to a molecular weight of,57.5 kDa. Peak 2 eluted at,15.20 ml, and was an artefact
of the in vitro ageing buffer. The migration of proteins of known molecular weight was used to calibrate the column – see inset. (B) Peak column
fractions were concentrated, resolved by 1D-PAGE, and stained with colloidal Coomassie blue (upper section), and Western blotted using specific
anti-synuclein antibodies (middle section). Beta-synuclein was not immunoprecipitated from either column fractions or aged synuclein reactions
when control serum was applied, and b-synuclein antibody did not cross-react with a-synuclein protein. Half of a mg of b-synuclein was similarly
blotted to provide a protein standard (lower section, left panel). Beta-synuclein was immunoprecipitated directly from in vitro aged fractions, with the
level of b-synuclein recovered confirmed by Western blotting. Parent b-synuclein protein as well as lower molecular weight proteolytic fragments
were recovered (marked with arrowheads). Two and a half mg of b-synuclein was similarly blotted to provide a protein standard (lower section, central
panel). Beta-synuclein immunoprecipitated from in vitro aged co-incubated mixtures, or from Superose 12 column peak fractions also detected the
presence of a-synuclein by Western blotting. Two and half mg of a-synuclein was similarly blotted to provide a protein standard (lower section, right
panel). The positions of protein molecular weight standards are also included on Western blots.
doi:10.1371/journal.pone.0061442.g008
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but to assign a contribution of the Pcmt12/2 neurological deficits
specifically to isoaspartate-damaged a-synuclein or b-synuclein is
not feasible; since PIMT regulates isoaspartate levels in a number
of other proteins known to be involved in these processes [16,52].
It has been suggested for Ab protein variants, (the primary
peptide/protein constituents of brain amyloid fibrils in AD
patients), that isoaspartate formation within Ab may enhance
the process of aggregation, and promote the conformational
change that drives b-turn formation for generation of stable
oligomeric b-sheet structures [24,53]. This may enhance peptide
stability, insolubility, and resistance to enzymatic degradation [53–
55]. This will need to be evaluated for isoaspartate-rich forms of a-
synuclein and b-synuclein, and how isoaspartate formation may
also influence the repertoire of other synuclein post-translational
modifications such as phosphorylation, ubiquitination, and protein
truncation. Furthermore, these other post-translational modifica-
tions of a-synuclein may also be influenced by co-incubation with
b-synuclein. Interestingly, the majority of truncated forms of a-
synuclein terminate with either an aspartic acid (Asp115, Asp119,
Asp135) or an asparagine residue (Asn122), which may arise from
limited proteolysis [56]. Since isoaspartate peptide linkages are
resistant to commonly encountered proteases [55], it remains to be
determined whether examples of a-synuclein truncation in vivo
arise from resistance to isoaspartate cleavage.
Finally, a comprehensive examination of the development of
isoaspartate in a-synuclein within the proteinaceous aggregates
that form in human synucleopathies will be of interest for future
studies. Isoaspartate protein damage could accumulate within a-
synuclein from sustained inactivation of PIMT, possibly as a
consequence of a reduction in the ratio of SAM:SAH [57], or
simply as a consequence of protein ageing if a-synuclein is
inaccessible to PIMT-mediated repair. Indeed, the inaccessibility
of Ab-peptide to PIMT repair may be the molecular mechanism
responsible for the increased isoaspartate levels that accumulate in
Ab-peptide examined from AD brain tissue [24,53,54]. By either
mechanism, an increase in the level of isoasparate within a-
synuclein may have pathological consequences that include an
increased propensity of protein aggregation and reduced protein
clearance via proteolytic resistance.
In summary, human a-synucleins and human b-synuclein are
proteins that are susceptible to a number of post-translational
modifications, which includes the formation of isoaspartate protein
damage. Since these two synuclein proteins are highly homolo-
gous, it is important to establish the differences in their molecular
behaviour that may contribute to their differential propensity to
contribute to synucleopathies. We have shown that b-synuclein is
relatively resistant to isoaspartate formation and able to ameliorate
its formation within a-synucleins, consistent with a neuroprotec-
tive action. It is provocative to consider that inhibition of
methyltransferases such as PIMT, which may arise through
lifestyle choices such as excessive alcohol consumption, could
result in increased isoaspartate protein damage within PIMT
substrates such as synucleins, and influence their (patho)physio-
logical activities.
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